Merck says study shows COVID-19 drug causes quick reduction in virus – Reuters

SUBMIT PHOTO: The Merck logo is seen at a gate to the Merck & & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid (Reuters) – U.S. drugmaker Merck & & Co Inc stated on Saturday the speculative antiviral drug molnupiravir it is establishing with Ridgeback Bio showed a quicker reduction in infectious infection in its phase 2a study among participants with early COVID-19.” The secondary objective findings in this study, of a quicker reduction in contagious infection among people with early COVID-19 treated with molnupiravir, are promising,” stated William Fischer, Associate Professor of Medicine at the University of North Carolina School of Medicine, in a declaration from the companies.The antiviral is being currently evaluated in a Phase 2/3 trial that is set to be completed in May.Merck decided to concentrate on therapies after its 2 COVID-19 vaccines failed to create preferred immune actions, prompting it to abandon the program in January.Reporting by Ann Maria Shibu in Bengaluru; Editing by Christian Schmollinger

Leave a Reply

Your email address will not be published. Required fields are marked *